RXRX
Recursion Pharmaceuticals Inc
3.80$
+8.2%
vs. previous close
Closing price · As of: Sep 18, 2026
Statements
Cash Flow
All figures per share in USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -0.34 | -0.27 | -0.93 | -0.48 | -1.38 | -1.31 | -0.83 | |
| 0.02 | 0.02 | 0.05 | 0.07 | 0.12 | 0.13 | 0.19 | |
| 0.01 | 0.03 | 0.09 | 0.16 | 0.26 | 0.30 | 0.25 | |
| 0.01 | 0.04 | 0.12 | 0.22 | – | – | – | |
| 0.00 | 0.19 | 0.00 | 0.60 | -0.21 | -0.14 | 0.03 | |
| 0.02 | 0.04 | 0.23 | 0.21 | 0.06 | 0.05 | 0.01 | |
| -0.02 | -0.05 | -1.60 | 1.10 | -0.05 | 0.95 | -0.04 | |
| – | – | 2.77 | – | – | – | – | |
| 0.00 | 0.04 | -0.08 | 0.00 | 0.00 | -0.02 | -0.02 | |
| 0.73 | 1.48 | 2.69 | 0.88 | 0.67 | 1.11 | 1.17 | |
| 0.36 | 1.16 | 0.17 | 1.50 | -0.76 | 0.74 | 0.34 | |
| -0.37 | -0.31 | -1.17 | -0.69 | -1.44 | -1.36 | -0.85 |
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.